ClinicalTrials.gg
RecruitingNCT06740214Updated Nov 24, 2025

Analgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block for Total Knee Arthroplasty

A Phase 3 interventional study of 0.5% standard bupivacaine only and 1.33% liposomal bupivacaine with 0.5% standard bupivacaine in Pain, Postoperative, Analgesic Effect and Total Knee Arthroplasty, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by The University of Hong Kong · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Pain, Postoperative by The University of Hong Kong — 3 open to participants now, 3 under way, 2 of them phase 3. Pain, Postoperative · The University of Hong Kong.

Planned enrollment
2nd of 11
177 · median 90
Started
2025
the only one that year
Phase 3
4 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies in Pain, Postoperative by The University of Hong Kong, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 3, and was the 13th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

3 of the 14 studies in Pain, Postoperative by The University of Hong Kong are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pain, Postoperative by The University of Hong Kong, or all of them as a file.
02

Study summary

Total knee arthroplasty is a commonly performed orthopaedic surgery for the treatment of end-stage osteoarthritis when conservative management becomes ineffective. TKA is associated with significant acute postoperative pain and many patients experience severe postoperative pain despite the use of multimodal analgesia. Poor acute postoperative pain control impacts rehabilitation, prolongs recovery and increases opioid consumption and chronic post-surgical pain.

Liposomal bupivacaine (Exparel, Pacira Pharmaceuticals Inc, Parsippany, New Jersey, USA) is a multivesicular formulation of bupivacaine that prolongs drug release and can extend the duration of analgesia. The adductor canal block (ACB) has been shown to reduce pain intensity and opioid consumption after total knee arthroplasty. The use of liposomal bupivacaine in the adductor canal block has recently been FDA-approved. However, the results of its efficacy from existing clinical trials have been mixed. In addition, the doses in the clinical trials have been different, and the optimal dose for perineural application of liposomal bupivacaine is unclear, including for the adductor canal block.

In this project, the investigators propose to conduct a randomized controlled trial to investigate the effect of different doses of liposomal bupivacaine in the adductor canal block on acute postoperative pain intensity and opioid consumption after robotic assisted total knee arthroplasty. The investigators will also assess secondary outcomes including knee functional scores, chronic pain and quality of recovery.

03

Conditions studied

  • Pain, Postoperative
  • Analgesic Effect
  • Total Knee Arthroplasty
  • Liposomal Bupivacaine
  • Dose Response Relationship, Drug

Browse trials for

Keywords

  • adductor canal block
  • local infiltration analgesia
  • liposomal bupivacaine
  • opioid consumption
  • total knee arthroplasty
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years old
  • Scheduled for elective primary unilateral total knee arthroplasty (TKA) with robotic surgery
  • Able to speak and understand Cantonese or Mandarin or English
  • Able to provide informed oral and written consent

Exclusion criteria

Exclusion Criteria:

  • Revision TKA
  • Single-stage bilateral TKA
  • Complex primary TKA requiring use of stem/augment/constrained liner
  • Surgeries with significant intraoperative complications which may alter rehabilitation protocol eg collateral ligament injury, fracture requiring fixation
  • Known allergy to opioids, local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDS) including COX-2 inhibitors
  • History of chronic pain other than chronic knee pain
  • History of
  • Chronic use of
  • Chronic opioid use (morphine, fentanyl, hydromorphone, ketobemidone, methadone, nicomorphine, oxycodone, or meperidine)
  • History of congestive heart failure ( 2)
  • Alcohol or drug abuse
  • Impaired renal function (defined as effective \< 30ml/min/1.73m2
  • Impaired liver function (defined as plasma over 34mol/L; [INR] >= 1.7, [ALT] over 100U/L, aspartate aminotransferase [AST] over 100U/L)
  • Coagulopathy ( count \<100,000/ml and/or INR >= 1.5) or the use of anticoagulants (not including aspirin) that precludes the use of adductor canal blocks
  • Pre-existing neurological or muscular disorders
  • Psychiatric illness
  • Impaired mental state
  • Pregnancy
  • Local infection
  • On immunosuppressants
  • High (BMI) (>=40)
  • Patient refusal for regional nerve blocks or to conduct clinical trial
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
177 participants (estimated)

Study arms

  • Active comparator
    ACB using 20ml 0.5% standard bupivacaine (SB-ACB)

    adductor canal block with 20ml 0.5% standard bupivacaine only

    Drug: 0.5% standard bupivacaine only

  • Experimental
    ACB using 10ml 1.33% liposomal bupivacaine with 10 ml 0.5% standard bupivacaine (LB10-ACB)

    adductor canal block with 10ml 1.33% liposomal bupivacaine (133mg) plus 10ml 0.5% standard bupivacaine

    Drug: 1.33% liposomal bupivacaine with 0.5% standard bupivacaine

  • Experimental
    ACB using 20ml 1.33% liposomal bupivacaine only (LB20-ACB)

    adductor canal block with 20ml 1.33% liposomal bupivacaine (266mg)

    Drug: 1.33% liposomal bupivacaine only

Interventions

  • Drug0.5% standard bupivacaine only

    20ml 0.5% standard bupivacaine only

  • Drug1.33% liposomal bupivacaine with 0.5% standard bupivacaine

    10ml 1.33% liposomal bupivacaine (133mg) plus 10ml 0.5% standard bupivacaine

  • Drug1.33% liposomal bupivacaine only

    20ml 1.33% liposomal bupivacaine (266mg)

06

What researchers measure

Primary outcomes

  1. Weighted area under curve (AUC) pain score

    Pain severity would be rated at rest after surgery using numerical rating scale (NRS) with 0 to 10 where 0=no pain and 10=the worst possible pain

    Time frame: The first 48 hours after surgery when the patient is at rest

Secondary outcomes

  1. NRS pain scores

    NRS pain scores at rest and with movement (active knee flexion) from after surgery to postoperative day (POD) 7, ranging 0-10, with higher scores indicating more severe pain.

    Time frame: from after surgery to postoperative day 7

  2. Oxynorm consumption

    Oxynorm consumption from postoperative day (POD) 1-7

    Time frame: Postoperative day 1-7

  3. Overall Benefit of Analgesic Score (OBAS)

    Overall Benefit of Analgesic Score (OBAS) from postoperative day (POD) 1-7 (range, 0 \[best\] to 28 \[worst\])

    Time frame: Postoperative day (POD) 1-7

  4. Plasma level of bupivacaine and ropivacaine

    Plasma level of bupivacaine and ropivacaine before and after surgery

    Time frame: Blood will be collected during induction, at 12 hours, 24 hours, 48 hours, and 72 hours after ACB.

  5. Quality of Recovery Questionnaire (QoR-9)

    Quality of Recovery Questionnaire (QoR-9) on postoperative day 1, ranging from 0 to 18, with higher scores indicating good recovery after anaesthesia.

    Time frame: Postoperative day 1

  6. Rehabilitation parameters (range of maximal active knee flexion)

    Range of maximal active knee flexion will be assessed by the physiotherapists while the patient is in hospital.

    Time frame: While the patient is in hospital from postoperative day 0, day 1, and day 2.

  7. Rehabilitation parameters (quadricep power)

    Quadricep power will be assessed by the physiotherapists while the patient is in hospital. Ratings: 0 - no muscle contraction 1. \- Move w/o gravity 2. \- Raise then drop down immediately 3. \- Raise against gravity w/o resistance 4. \- Raise against gravity w/some resistance 5. \- Raise against gravity w/ full resistance

    Time frame: While the patient is in hospital from postoperative day 0, day 1, and day 2.

  8. Rehabilitation parameters (ability to perform straight leg raising)

    Ability to perform straight leg raising will be assessed by the physiotherapists while the patient is in hospital. Ratings (Yes/ No).

    Time frame: While the patient is in hospital from postoperative day 0, day 1, and day 2.

  9. Rehabilitation parameters (walking distance)

    Walking distance (in metres) will be assessed by the physiotherapists while the patient is in hospital.

    Time frame: While the patient is in hospital from postoperative day 0, day 1, and day 2.

  10. Rehabilitation parameters (Duration of hospital stay)

    No. of hospitalization days from admission to discharge

    Time frame: estimated on average of postoperative day 7 at the date of discharge from hospital

  11. Rehabilitation parameters (discharge location)

    Home or rehabilitation center

    Time frame: estimated on average of postoperative day 7 at the date of discharge from hospital

  12. Opioid-related side effects

    Presence or absence of pruritus, dizziness, nausea, and vomiting will be recorded.

    Time frame: While the patient is in hospital from postoperative day 0, 1, and 2.

  13. Potential side effects related to adductor canal block (ACB)

    Presence or absence of local anaesthetic toxicity, neurological injury, and intravascular injection will be recorded.

    Time frame: While the patient is in hospital from postoperative day 0, 1, and 2.

  14. Analgesic block duration

    Measured in time to return of pain (When did your pain relief from the block completely wear off?), time to sensory resolution (When did your numbness completely resolve and return to normal?), and time to motor resolution (When did your arm or hand weakness resolve and return to normal?)

    Time frame: While the patient is in hospital at postoperative day 1

  15. Sensory and motor assessment

    The affected lower limb will be measured. Sensory assessment (Sensation to pin prick), rating from 0 (no sensation) to 10 (normal sensation) Motor assessment * Straight leg raising achieved Ratings (Yes/ No) * Quadriceps power Ratings: 0 - no muscle contraction 1. \- Move w/o gravity 2. \- Raise then drop down immediately 3. \- Raise against gravity w/o resistance 4. \- Raise against gravity w/some resistance 5. \- Raise against gravity w/ full resistance

    Time frame: While the patient is in hospital from post-block 2 hours, 6 hours, 12 hours, and 24 hours.

  16. quality of life (SF12v2)

    Eight domains of SF-12v2 (HK) are measured on a scale ranging from 0 to 100. A higher domain score indicates a better HRQoL.

    Time frame: at 6 weeks and at 3 and 6 months after surgery

  17. Identification Pain Questionnaire for Neuropathic Pain (ID-NeP)

    Neuropathic pain will be assessed using Identification Pain Questionnaire for Neuropathic Pain (ID-NeP), consisting of six items: "Yes" answers to questions 1-5 were given a score of 1, while "yes" answer to question 6 scored -1. "No" answers to questions 1-5 were given a score of 0, while "yes" answer to question 6 scored 0.

    Time frame: at 6 weeks, 3 months and 6 months postoperatively

  18. Knee Society Knee Function Score

    Knee Society Knee Function Score at 6 weeks, 3 months and 6 months postoperatively, from 0 to 100 with lower scores being indicative of worse knee conditions and higher scores being indicative of better knee conditions.

    Time frame: at 6 weeks, 3 months and 6 months postoperatively

  19. Chronic post-surgical pain

    The presence or absence of chronic post-surgical pain, pain scores if present.

    Time frame: at 6 weeks, 3 months and 6 months postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Culliton SE, Bryant DM, MacDonald SJ, Hibbert KM, Chesworth BM. Validity and Internal Consistency of the New Knee Society Knee Scoring System. Clin Orthop Relat Res. 2018 Jan;476(1):77-84. doi: 10.1007/s11999.0000000000000014. PubMed 29529620 ↗
  • Portenoy R. Development and testing of a neuropathic pain screening questionnaire: ID Pain. Curr Med Res Opin. 2006 Aug;22(8):1555-65. doi: 10.1185/030079906X115702. PubMed 16870080 ↗
  • Chan MT, Lo CC, Lok CK, Chan TW, Choi KC, Gin T. Psychometric testing of the Chinese quality of recovery score. Anesth Analg. 2008 Oct;107(4):1189-95. doi: 10.1213/ane.0b013e318184b94e. PubMed 18806027 ↗
  • Lam ET, Lam CL, Fong DY, Huang WW. Is the SF-12 version 2 Health Survey a valid and equivalent substitute for the SF-36 version 2 Health Survey for the Chinese? J Eval Clin Pract. 2013 Feb;19(1):200-8. doi: 10.1111/j.1365-2753.2011.01800.x. Epub 2011 Nov 29. PubMed 22128754 ↗
  • Lehmann N, Joshi GP, Dirkmann D, Weiss M, Gulur P, Peters J, Eikermann M. Development and longitudinal validation of the overall benefit of analgesia score: a simple multi-dimensional quality assessment instrument. Br J Anaesth. 2010 Oct;105(4):511-8. doi: 10.1093/bja/aeq186. Epub 2010 Aug 6. PubMed 20693179 ↗
  • Cohen, J., Statistical power analysis for the behavioral sciences. 2013: routledge.
  • Quaye A, McAllister B, Garcia JR, Nohr O, Laduzenski SJ, Mack L, Kerr CR, Kerr DA, Razafindralay CN, Richard JM, Craig WY, Rodrigue S. A prospective, randomized trial of liposomal bupivacaine compared to conventional bupivacaine on pain control and postoperative opioid use in adults receiving adductor canal blocks for total knee arthroplasty. Arthroplasty. 2024 Feb 1;6(1):6. doi: 10.1186/s42836-023-00226-y. PubMed 38297390 ↗
  • Malige A, Pellegrino AN, Kunkle K, Konopitski AK, Brogle PJ, Nwachuku CO. Liposomal Bupivacaine in Adductor Canal Blocks Before Total Knee Arthroplasty Leads to Improved Postoperative Outcomes: A Randomized Controlled Trial. J Arthroplasty. 2022 Aug;37(8):1549-1556. doi: 10.1016/j.arth.2022.03.073. Epub 2022 Mar 26. PubMed 35351553 ↗
  • Hungerford M, Neubauer P, Ciotola J, Littleton K, Boner A, Chang L. Liposomal Bupivacaine vs Ropivacaine for Adductor Canal Blocks in Total Knee Arthroplasty: A Prospective Randomized Trial. J Arthroplasty. 2021 Dec;36(12):3915-3921. doi: 10.1016/j.arth.2021.08.017. Epub 2021 Aug 21. PubMed 34556382 ↗
  • Hubler CP, Bevil KM, Greiner JJ, Hetzel SJ, Borden SB, Cios HA. Liposomal Bupivacaine Versus Standard Bupivacaine in the Adductor Canal for Total Knee Arthroplasty: A Randomized, Controlled Trial. Orthopedics. 2021 Jul-Aug;44(4):249-255. doi: 10.3928/01477447-20210621-01. Epub 2021 Jul 1. PubMed 34292820 ↗
  • Lv J, Huang C, Wang Z, Ou S. Adductor canal block combined with local infiltration analgesia versus isolated adductor canal block in reducing pain and opioid consumption after total knee arthroplasty: a systematic review and meta-analysis. J Int Med Res. 2020 Aug;48(8):300060520926075. doi: 10.1177/0300060520926075. PubMed 32776794 ↗
  • Li Y, Li A, Zhang Y. The efficacy of combined adductor canal block with local infiltration analgesia for pain control after total knee arthroplasty: A meta-analysis. Medicine (Baltimore). 2018 Dec;97(49):e13326. doi: 10.1097/MD.0000000000013326. PubMed 30544393 ↗
  • Zuo W, Guo W, Ma J, Cui W. Dose adductor canal block combined with local infiltration analgesia has a synergistic effect than adductor canal block alone in total knee arthroplasty: a meta-analysis and systematic review. J Orthop Surg Res. 2019 Apr 11;14(1):101. doi: 10.1186/s13018-019-1138-5. PubMed 30971284 ↗
  • Ilfeld BM, Eisenach JC, Gabriel RA. Clinical Effectiveness of Liposomal Bupivacaine Administered by Infiltration or Peripheral Nerve Block to Treat Postoperative Pain. Anesthesiology. 2021 Feb 1;134(2):283-344. doi: 10.1097/ALN.0000000000003630. PubMed 33372949 ↗
  • Jiang X, Wang QQ, Wu CA, Tian W. Analgesic Efficacy of Adductor Canal Block in Total Knee Arthroplasty: A Meta-analysis and Systematic Review. Orthop Surg. 2016 Aug;8(3):294-300. doi: 10.1111/os.12268. PubMed 27627711 ↗
  • Rawal N. Current issues in postoperative pain management. Eur J Anaesthesiol. 2016 Mar;33(3):160-71. doi: 10.1097/EJA.0000000000000366. PubMed 26509324 ↗
  • Lavand'homme PM, Kehlet H, Rawal N, Joshi GP; PROSPECT Working Group of the European Society of Regional Anaesthesia and Pain Therapy (ESRA). Pain management after total knee arthroplasty: PROcedure SPEcific Postoperative Pain ManagemenT recommendations. Eur J Anaesthesiol. 2022 Sep 1;39(9):743-757. doi: 10.1097/EJA.0000000000001691. Epub 2022 Jul 20. PubMed 35852550 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.

Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 21 months is close to that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2024
First posted
Dec 18, 2024
StartActual
Sep 4, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06740214
Responsible party
Wong Sau Ching Stanley (Clinical Associate Professor, The University of Hong Kong) — Principal investigator
First posted
Dec 18, 2024
Start date
Sep 4, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 24, 2025

Study contacts

Stanley S.C. WONG, MD (HKU)
Contact
wongstan@hku.hk
(852) 2255 3303

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion